Spartan Bioscience Announces Clinical Technology as Distributor for Rapid CYP2C19 Testing System

Share Article

Sample-to-result system has FDA 510(k) clearance and provides CYP2C19 test results in 60 minutes.

Spartan RX CYP2C19 System

Spartan’s rapid CYP2C19 testing system is an exciting breakthrough for personalized medicine.” -Dennis Forchione, President and Owner of Clinical Technology

Spartan Bioscience today announced Clinical Technology Inc. as the distributor for its rapid CYP2C19 testing system in the eastern Midwest region of the United States.

The Spartan RX CYP2C19 System provides CYP2C19 test results in less than 60 minutes from a non-invasive cheek swab. It helps doctors determine therapeutic strategies for drugs metabolized by the CYP450 2C19 genetic pathway, which include anti-platelet therapies, beta blockers and proton pump inhibitors. The sample-to-result system has received FDA 510(k) clearance in the United States.

“Clinical Technology is a leading supplier of new and innovative medical technologies across the Midwest,” said Paul Lem, M.D., CEO of Spartan Bioscience. “Clinical Technology has developed strong relationships with doctors and hospitals over 35 years, and we look forward to a prosperous partnership.”

“Spartan’s rapid CYP2C19 testing system is an exciting breakthrough for personalized medicine,” said Dennis Forchione, President and Owner of Clinical Technology. “Doctors and patients want faster results and this is an ideal solution.”

About CYP2C19
The CYP2C19 enzyme metabolizes approximately 15 percent of all prescribed drugs(1), including important drug classes such as anti-platelet therapies, beta blockers, anti-depressants, proton pump inhibitors, and anti-epileptics. About 30% of Caucasians, 40% of Africans, and more than 50% of Asians and Indians carry CYP2C19 gene variants that reduce response to drugs metabolized by CYP2C19.(2,3,4,5)

About Spartan Bioscience
Spartan Bioscience is the leader in on-demand DNA testing.(6) Spartan is bringing complete sample-to-result DNA testing systems to medicine. Spartan’s technology fully integrates DNA collection, extraction, and analysis, with an intuitive interface that is easy to operate. For the first time, healthcare providers and their patients can get DNA results on demand. For more information, please visit our website at: http://www.spartanbio.com.

The Spartan logo is a registered trademark of Spartan Bioscience Inc.

1. dbSNP Short Genetic Variations. Reference SNP (refSNP) Cluster Report: rs12248560
2. Damani SB, Topol EJ. (2010). J Am Coll Cardiol. 56:109–11.
3. Chen M et al. (2011). Atherosclerosis. 220(1):168–71.
4. Oh IY et al. (2012). Heart. 98(2):139–44.
5. Jose R et al. (2004). Fundamental & Clinical Pharmacology. 19(1): 101–105.
6. Roberts JD et al. (2012). Lancet. 379:1705–11.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kira Watson
Spartan Bioscience Inc.
+1 613-228-7756 Ext: 708
Email >
Visit website